Send to

Choose Destination
J Am Acad Dermatol. 2002 Nov;47(5):785-8.

Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder.

Author information

Division of Dermatology & Cutaneous Sciences, and the Firefighter's Burn Treatment Unit & Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.


Rituximab, a chimeric monoclonal antibody directed against CD20 of B cells, has been reported to be effective in the treatment of B-cell lymphomas and malignant and nonmalignant plasma cell-dependent diseases. We describe a 30-year-old woman with refractory pemphigus vulgaris who experienced a partial remission after treatment with rituximab.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center